265 related articles for article (PubMed ID: 23955767)
1. A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?
Santiago T; Santiago MG; Rovisco J; Duarte C; Malcata A; da Silva JA
Clin Rheumatol; 2013 Dec; 32(12):1819-22. PubMed ID: 23955767
[TBL] [Abstract][Full Text] [Related]
2. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
Aghdashi MA; Khadir M; Dinparasti-Saleh R
Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
[TBL] [Abstract][Full Text] [Related]
3. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.
Shovman O; Tamar S; Amital H; Watad A; Shoenfeld Y
Clin Rheumatol; 2018 Feb; 37(2):563-568. PubMed ID: 29063464
[TBL] [Abstract][Full Text] [Related]
4. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.
Akgül Ö; Kılıç G; Kılıç E; Cüce İ; Özgöçmen S
Rheumatol Int; 2014 Mar; 34(3):443-4. PubMed ID: 23263496
[No Abstract] [Full Text] [Related]
5. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA
Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266
[TBL] [Abstract][Full Text] [Related]
6. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
8. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
9. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
10. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
11. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.
Giardina AR; Ferrante A; Ciccia F; Impastato R; Miceli MC; Principato A; Triolo G
Rheumatol Int; 2010 Sep; 30(11):1437-40. PubMed ID: 19851772
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor inhibitor-related lupus: safety of switching agents.
Luong JM; Tan BT; Buchanan RR; Schachna L
Clin Rheumatol; 2010 May; 29(5):551-3. PubMed ID: 20119843
[TBL] [Abstract][Full Text] [Related]
13. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.
Schulz M; Dotzlaw H; Neeck G
Biomed Res Int; 2014; 2014():675108. PubMed ID: 24783218
[TBL] [Abstract][Full Text] [Related]
14. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-induced lupus.
Williams EL; Gadola S; Edwards CJ
Rheumatology (Oxford); 2009 Jul; 48(7):716-20. PubMed ID: 19416947
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab.
Mounach A; Ghazi M; Nouijai A; Ghozlani I; Achemlal L; Bezza A; El Maghraoui A
Clin Exp Rheumatol; 2008; 26(6):1116-8. PubMed ID: 19210883
[TBL] [Abstract][Full Text] [Related]
17. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
Cohen G; Courvoisier N; Cohen JD; Zaltni S; Sany J; Combe B
Clin Exp Rheumatol; 2005; 23(6):795-800. PubMed ID: 16396697
[TBL] [Abstract][Full Text] [Related]
18. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha antagonist induced lupus on three different agents.
Mudduluru BM; Shah S; Shamah S; Swaminath A
Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
